K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value

Table 3

KRAS and sensitivity to anti-EGFR agents in phase III trial.

Trial	Anti-EGFR agent	Total number of patients (𝑛)	Patients tested for KRAS (𝑛)	KRAS mutant 𝑛 (%)	Survival in KRAS mutant (HR)
TRIBUTE [46]	Gefitinib	1079	264	55 (21)	2.1*
BR. 21 [47]	Erlotinib	731	206	30 (15)	1.67
SATURN [48]	Erlotinib	889	493	90 (18)	0.79
ATLAS [15]	Erlotinib	768	NR	NR	0.92
INTEREST [49]	Gefitinib	1466	275	49 (18)	0.91
FLEX [57]	Cetuximab	1125	379	72 (19)	1.0
BMS099 [56]	Cetuximab	676	202	35 (17)	0.95

HR: hazard ratio; NR: not reported. *Statistically significant.